FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2466689542> ?p ?o ?g. }

• W2466689542 abstract "Abstract Abstract 3831 Background: ABVD is the standard treatment for advanced stage Hodgkin Lymphoma (HL) with rates of complete remission achieved in the majority of patients treated. Current practice guidelines (American Society of Clinical Oncology, Smith TJ et al. JCO 2008) recommend the use of granulocyte colony stimulating factor (G-CSF) in secondary prophylaxis despite lack of a survival benefit and potential toxicities, including bleomycin pulmonary toxicity (BPT). Recently, small retrospective series and expert opinion (Horning S, ASH Education Program Book 2007) advocate for the omission of G-CSF, although this approach has not been prospectively studied. The purpose of this study was to perform a decision analysis that compared the life expectancy and quality-adjusted life expectancy of advanced-stage HL managed with and without secondary prophylactic G-CSF. Methods: We constructed a decision-analytic model to compare the strategy of secondary prophylaxis with G-CSF to a strategy of no G-CSF with severe neutropenia for a hypothetical cohort of 40 year-old patients with clinical stage IIB to IV Hodgkin Lymphoma treated with 8 cycles of ABVD chemotherapy. Markov models were used to simulate a 2-year clinical course of patients. Baseline probability estimates were derived from a systematic review of relevant published studies. Utilities for various health states were derived from expert opinion. One-way sensitivity analysis was performed on key variables such as severe neutropenia, febrile neutropenia and bleomycin pulmonary toxicity, as well as the utilites associated with these health states. Results: The life expectancy was 1.858 years for the G-CSF strategy and 1.875 years for no G-CSF, yielding a net expected benefit of 0.017 years for no G-CSF use in severe neutropenia. The quality-adjusted life expectancy was 1.371 years for the G-CSF strategy and 1.408 years for no G-CSF with a net expected benefit for no G-CSF of 0.037 QALYs. On microsimulation (10,000 trials), 96% of the simulations showed that the no G-CSF strategy is preferred to the use of G-CSF. This analysis was not sensitive to the odds ratio of lung toxicity with G-CSF, the hazard ratios of febrile neutropenia and severe neutropenia, the probability of death from febrile neutropenia, or the utilities associated with bleomycin pulmonary toxicity, hospitalization for febrile neutropenia and musculoskeletal pain from G-CSF. Conclusions: While the difference between the two strategies is small, our model predicted that for a 40 year-old patient with advanced-stage Hodgkin Lymphoma treated with ABVD chemotherapy, the strategy of avoiding use of G-CSF with severe neutropenia is preferred. This finding is robust across a wide range of sensitivity analyses. Disclosures: No relevant conflicts of interest to declare." @default.
• W2466689542 created "2016-07-22" @default.
• W2466689542 creator A5008282524 @default.
• W2466689542 creator A5024269299 @default.
• W2466689542 creator A5042150387 @default.
• W2466689542 creator A5044632878 @default.
• W2466689542 date "2010-11-19" @default.
• W2466689542 modified "2023-09-27" @default.
• W2466689542 title "G-CSF as Secondary Prophylaxis of Febrile Neutropenia In the Management of Advanced-Stage Hodgkin Lymphoma Treated with ABVD Chemotherapy: A Decision Analysis." @default.
• W2466689542 doi "https://doi.org/10.1182/blood.v116.21.3831.3831" @default.
• W2466689542 hasPublicationYear "2010" @default.
• W2466689542 type Work @default.
• W2466689542 sameAs 2466689542 @default.
• W2466689542 citedByCount "0" @default.
• W2466689542 crossrefType "journal-article" @default.
• W2466689542 hasAuthorship W2466689542A5008282524 @default.
• W2466689542 hasAuthorship W2466689542A5024269299 @default.
• W2466689542 hasAuthorship W2466689542A5042150387 @default.
• W2466689542 hasAuthorship W2466689542A5044632878 @default.
• W2466689542 hasConcept C126322002 @default.
• W2466689542 hasConcept C133925201 @default.
• W2466689542 hasConcept C141071460 @default.
• W2466689542 hasConcept C143998085 @default.
• W2466689542 hasConcept C177713679 @default.
• W2466689542 hasConcept C2776305933 @default.
• W2466689542 hasConcept C2776694085 @default.
• W2466689542 hasConcept C2776755627 @default.
• W2466689542 hasConcept C2777063308 @default.
• W2466689542 hasConcept C2777132456 @default.
• W2466689542 hasConcept C2778336483 @default.
• W2466689542 hasConcept C2778850193 @default.
• W2466689542 hasConcept C2779429289 @default.
• W2466689542 hasConcept C2908647359 @default.
• W2466689542 hasConcept C71924100 @default.
• W2466689542 hasConcept C74133956 @default.
• W2466689542 hasConcept C99454951 @default.
• W2466689542 hasConceptScore W2466689542C126322002 @default.
• W2466689542 hasConceptScore W2466689542C133925201 @default.
• W2466689542 hasConceptScore W2466689542C141071460 @default.
• W2466689542 hasConceptScore W2466689542C143998085 @default.
• W2466689542 hasConceptScore W2466689542C177713679 @default.
• W2466689542 hasConceptScore W2466689542C2776305933 @default.
• W2466689542 hasConceptScore W2466689542C2776694085 @default.
• W2466689542 hasConceptScore W2466689542C2776755627 @default.
• W2466689542 hasConceptScore W2466689542C2777063308 @default.
• W2466689542 hasConceptScore W2466689542C2777132456 @default.
• W2466689542 hasConceptScore W2466689542C2778336483 @default.
• W2466689542 hasConceptScore W2466689542C2778850193 @default.
• W2466689542 hasConceptScore W2466689542C2779429289 @default.
• W2466689542 hasConceptScore W2466689542C2908647359 @default.
• W2466689542 hasConceptScore W2466689542C71924100 @default.
• W2466689542 hasConceptScore W2466689542C74133956 @default.
• W2466689542 hasConceptScore W2466689542C99454951 @default.
• W2466689542 hasLocation W24666895421 @default.
• W2466689542 hasOpenAccess W2466689542 @default.
• W2466689542 hasPrimaryLocation W24666895421 @default.
• W2466689542 hasRelatedWork W1721476926 @default.
• W2466689542 hasRelatedWork W1907090170 @default.
• W2466689542 hasRelatedWork W1979101648 @default.
• W2466689542 hasRelatedWork W2038671854 @default.
• W2466689542 hasRelatedWork W2093590450 @default.
• W2466689542 hasRelatedWork W2095611248 @default.
• W2466689542 hasRelatedWork W2128830492 @default.
• W2466689542 hasRelatedWork W2161015468 @default.
• W2466689542 hasRelatedWork W2215157211 @default.
• W2466689542 hasRelatedWork W2335974905 @default.
• W2466689542 hasRelatedWork W2411207388 @default.
• W2466689542 hasRelatedWork W2416340253 @default.
• W2466689542 hasRelatedWork W2495588438 @default.
• W2466689542 hasRelatedWork W2574201053 @default.
• W2466689542 hasRelatedWork W2736111722 @default.
• W2466689542 hasRelatedWork W2885814352 @default.
• W2466689542 hasRelatedWork W2926097581 @default.
• W2466689542 hasRelatedWork W3083763733 @default.
• W2466689542 hasRelatedWork W3112963483 @default.
• W2466689542 hasRelatedWork W652352161 @default.
• W2466689542 isParatext "false" @default.
• W2466689542 isRetracted "false" @default.
• W2466689542 magId "2466689542" @default.
• W2466689542 workType "article" @default.